Artiva Biotherapeutics Given Buy Rating at Needham Company LLC
| ARTV Stock | 10.40 0.22 2.07% |
Slightly above 55% of Artiva Biotherapeutics,'s sophisticated investors are presently thinking to get in. The analysis of the overall investor sentiment regarding Artiva Biotherapeutics, Common suggests that some traders are interested. Artiva Biotherapeutics,'s investing sentiment can be driven by a variety of factors including economic data, Artiva Biotherapeutics,'s earnings reports, geopolitical events, and overall market trends.
Artiva |
Needham Company LLC reaffirmed their buy rating on shares of Artiva Biotherapeutics in a report published on Wednesday,Benzinga reports. Needham Company LLC currently has a 23.00 price target on the stock. A number of other research firms have also recently weighed in on ARTV. Wedbush reaffirmed an outperform rating
Read at thelincolnianonline.com
 |
Artiva Biotherapeutics, Fundamental Analysis
We analyze Artiva Biotherapeutics,'s financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Artiva Biotherapeutics, using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Artiva Biotherapeutics, based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Price To Sales
Price To Sales Comparative Analysis
Artiva Biotherapeutics, is currently under evaluation in price to sales category among its peers. Price to Sales ratio is typically used for valuing equity relative to its own past performance as well as to performance of other companies or market indexes. In most cases, the lower the ratio, the better it is for investors. However, it is advisable for investors to exercise caution when looking at price-to-sales ratios across different industries.
Artiva Biotherapeutics, Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Artiva Biotherapeutics, stock to make a market-neutral strategy. Peer analysis of Artiva Biotherapeutics, could also be used in its relative valuation, which is a method of valuing Artiva Biotherapeutics, by comparing valuation metrics with similar companies.
Peers
Artiva Biotherapeutics, Related Equities
| CHD | Church Dwight | 0.00 |
| ||
| LECO | Lincoln Electric | 0.03 |
| ||
| FSP | Franklin Street | 0.48 |
| ||
| UL | Unilever PLC | 1.20 |
| ||
| EWCZ | European Wax | 1.72 |
| ||
| ACU | Acme United | 1.79 |
| ||
| ATEX | Anterix | 2.60 |
|
Additional Tools for Artiva Stock Analysis
When running Artiva Biotherapeutics,'s price analysis, check to measure Artiva Biotherapeutics,'s market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Artiva Biotherapeutics, is operating at the current time. Most of Artiva Biotherapeutics,'s value examination focuses on studying past and present price action to predict the probability of Artiva Biotherapeutics,'s future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Artiva Biotherapeutics,'s price. Additionally, you may evaluate how the addition of Artiva Biotherapeutics, to your portfolios can decrease your overall portfolio volatility.